Annexon (NASDAQ:ANNX) Downgraded to Strong Sell Rating by Wall Street Zen

Wall Street Zen cut shares of Annexon (NASDAQ:ANNX) from a sell rating to a strong sell rating in a report published on Saturday.

Several other equities analysts have also issued reports on the company. HC Wainwright reaffirmed a “buy” rating and issued a $14.00 price target on shares of Annexon in a research report on Monday, July 20th. Weiss Ratings reissued a “sell (d-)” rating on shares of Annexon in a research report on Friday, July 17th. Cantor Fitzgerald restated an “overweight” rating on shares of Annexon in a research note on Monday, July 13th. Needham & Company LLC raised their price objective on shares of Annexon from $11.00 to $25.00 and gave the company a “buy” rating in a research note on Wednesday, July 15th. Finally, Citizens Jmp raised shares of Annexon from an “underperform” rating to a “market perform” rating in a report on Thursday. Five equities research analysts have rated the stock with a Buy rating, three have given a Hold rating and two have issued a Sell rating to the company’s stock. According to MarketBeat, Annexon currently has an average rating of “Hold” and a consensus price target of $15.33.

Annexon Stock Up 0.6%

ANNX stock opened at $5.29 on Friday. The business has a 50 day moving average of $5.35 and a 200 day moving average of $5.51. The firm has a market cap of $1.00 billion, a PE ratio of -4.56 and a beta of 1.18. Annexon has a twelve month low of $2.03 and a twelve month high of $7.18.

Annexon (NASDAQ:ANNX) last released its earnings results on Wednesday, August 12th. The company reported ($0.28) EPS for the quarter, missing the consensus estimate of ($0.24) by ($0.04). On average, research analysts expect that Annexon will post -1 earnings per share for the current fiscal year.

Insider Buying and Selling at Annexon

In related news, Director Muneer A. Satter acquired 613,497 shares of the firm’s stock in a transaction dated Thursday, May 28th. The stock was purchased at an average cost of $5.41 per share, with a total value of $3,319,018.77. Following the completion of the acquisition, the director directly owned 10,342,134 shares of the company’s stock, valued at approximately $55,950,944.94. This trade represents a 6.31% increase in their ownership of the stock. The acquisition was disclosed in a document filed with the SEC, which is accessible through the SEC website. 10.31% of the stock is owned by insiders.

Institutional Investors Weigh In On Annexon

A number of large investors have recently added to or reduced their stakes in the stock. CIBC Bancorp USA Inc. purchased a new stake in Annexon during the 3rd quarter valued at $31,000. Engineers Gate Manager LP purchased a new position in shares of Annexon in the 2nd quarter worth $32,000. Mirae Asset Global Investments Co. Ltd. boosted its stake in shares of Annexon by 65.6% in the 4th quarter. Mirae Asset Global Investments Co. Ltd. now owns 7,033 shares of the company’s stock worth $35,000 after buying an additional 2,785 shares during the last quarter. Landscape Capital Management L.L.C. bought a new stake in shares of Annexon in the fourth quarter worth $50,000. Finally, Mercer Global Advisors Inc. ADV bought a new stake in shares of Annexon in the fourth quarter worth $52,000.

Trending Headlines about Annexon

Here are the key news stories impacting Annexon this week:

• Positive Sentiment: HC Wainwright maintained its Buy rating and $14 price target, substantially above Annexon’s recent trading level. This indicates the firm continues to see significant potential upside despite lowering its earnings projections. HC Wainwright analyst estimates
• Neutral Sentiment: Citizens JMP upgraded Annexon to Market Perform, suggesting a more constructive stance but not an outright bullish recommendation. Citizens JMP upgrades Annexon
• Negative Sentiment: HC Wainwright reduced its EPS forecasts across 2026–2030, including estimates of $(0.99) for 2026, $(0.74) for 2027, $(0.39) for 2028, $0.03 for 2029 and $0.45 for 2030. The cuts imply slower expected earnings improvement and could weigh on investor sentiment, even though the firm retained its Buy rating and $14 target. HC Wainwright lowers Annexon earnings estimates
• Negative Sentiment: Wall Street Zen lowered its rating on Annexon, adding another negative signal from the analyst community. Wall Street Zen lowers Annexon rating
• Negative Sentiment: Annexon shares previously gapped down after weak earnings. The company reported a quarterly loss of $0.28 per share, worse than the $0.24 consensus estimate, reinforcing concerns about ongoing cash needs and the timing of profitability. Annexon shares gap down following weak earnings

Annexon Company Profile

Annexon Inc is a clinical-stage biotechnology company focused on the discovery and development of complement-targeted therapies for patients with neurodegenerative and neuroimmune diseases. The company’s research platform centers on the inhibition of the C1 complex, a key initiator of the classical complement pathway implicated in several rare and life-threatening disorders. By selectively targeting upstream complement activation, Annexon aims to prevent the aberrant immune-mediated damage that characterizes conditions such as Guillain-Barré syndrome (GBS) and autoimmune neuropathies.

At the core of Annexon’s pipeline is ANX005, a humanized monoclonal antibody directed against the C1q subcomponent, currently in Phase 2 clinical trials for acute GBS and chronic neurodegenerative indications.